| Customization: | Available |
|---|---|
| Quality Standard: | USP, Bp |
| Package: | 3*10 Tablets |
|
Still deciding? Get samples of US$ 0.01/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Generic Name | Paroxetine Hydrochloride Tablets |
| Strength | 10mg |
| Packing | 3*10 Tablets/box |
| Origin | China |
Value-added services:
Packaging design by our team
Registration service by our team
Registration dossier available by our team
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Product name:
Paroxetine Hydrochloride Tablets
Character:
This product is a white oval, double-sided raised film coated sheet.
Indications:
Paroxetine hydrochloride tablets are indicated for the treatment of various types of depression, including depression with anxiety and reactive depression. Common depressive symptoms: fatigue, sleep disturbances, lack of interest and pleasure in daily activities, loss of appetite. To treat obsessive-compulsive neurosis. Common obsessive-compulsive symptoms: Feeling repeated and persistent thoughts, impulses, or imaginings that can cause significant anxiety, leading to repetitive behaviors or mental activities. Treatment of panic disorder with or without agoraphobia. Common panic attack symptoms: palpitations, sweating, shortness of breath, chest pain, nausea, tingling, and near-death. Treatment of social phobia/social anxiety disorder. Common symptoms of social anxiety: palpitations, sweating, shortness of breath, etc. Often manifested as secondary to a significant or persistent fear of one or more social situations or performance situations, leading to avoidance. After satisfactory treatment, continued use of this product can prevent the recurrence of depression, panic disorder and obsessive-compulsive disorder.
Drug overdose:
The available data show that this product has a large safety range. There have been reports of drug overdose with a single dose of 2000mg or in combination with other drugs (including alcohol). Experience with overdose has shown that in addition to those symptoms mentioned in the adverse reactions section, nausea, vomiting, dilated pupils, fever, blood pressure changes, headache, involuntary muscle contractions, agitation, anxiety, and tachycardia have been reported. Episodes of coma or electrocardiogram changes have been reported occasionally, but are rare and life-threatening and occur with or without the use of other psychiatric drugs.
There is no specific antidote and it can be treated in the usual way for other antidepressant overdoses. Patients can be treated according to clinically applicable methods or as recommended by the national poison Control Center.
Pharmacology and toxicology:
Pharmacological action
Paroxetine hydrochloride is an antidepressant and is a potent, highly selective 5-HT reuptake inhibitor. It can increase the concentration of 5-HT in synaptic cleft. Enhance central 5-hydroxytryptaminergic nerve function. It only weakly inhibits the reuptake of norepinephrine and dopamine. It has little affinity with muscarinic receptors or α1, α2, beta-adrenergic receptors, dopamine receptors (D2), 5-HT1 receptors, 5-HT2 receptors, and histamine (H1) receptors. There was no inhibition on monoamine oxidase.
Toxicological study
Genotoxicity:
Paroxetine Ames test, mouse lymphoma test, extra-programmed DNA synthesis test. The chromosomal aberration test of human lymphocytes, micronucleus test of mice and dominant lethal test of rats were negative.
Reproductive toxicity:
Paroxetine was given 15mg/kg/ day (in mg/m2, 2.9 times the clinically recommended dose for depression). The pregnancy rate of rats decreased. In toxicity studies from 2 to 52 weeks. Irreversibly damaged reproductive tract was found in male rats (epididymal duct epithelial vacuoles were observed at 50mg/kg/ day. 2 Smg/kg/ day atrophy of Zhaopill delivery tube with inhibition of seed production). Paroxetine was given 50mg/kg/ day in organoforming rats and 6mg/kg/ day in rabbits (calculated in mg/m2). Equivalent to 8 and 2 times the clinically recommended dose for depression, respectively). No teratogenic effect was observed. However, the drug was administered continuously after the first trimester of pregnancy and throughout lactation. During the first 4 days of lactation, the death of the pups increased. This action occurs at 1g/kg/ day. The cause of death was not immediately known. It was not possible to determine the dose of no effect that caused the death of the young rats.
carcinogenicity
In the carcinogenicity test of rodent dosing method for two years. Mice and rats were given doses of 25mg/kg and 20mg/kg per day, respectively (calculated in mg/m2, equivalent to 3.9 times the clinically recommended dose for depression, respectively). Results The incidence of reticulocytoma was significantly increased in the high-dose male rats (control. Low. The medium and high dose groups were 1/0, 0/50.0/50 and 4/50, respectively). The incidence of lymphoreticuloendothelioma increased dose-dependent. No effect was seen in female rats. The number of tumors in mice showed a dose-dependent increase. There was no drug-related increase in the number of mice with tumors. The relevance of these findings to humans is unclear.
Storage:
Shade, seal and store in a dry place.
){kind=link}